cd4+cd25+ regulatory t cells
Advanced Hematologic Malignancies
Stanford UniversityCell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
5 Active assets in the Advanced Hematologic Malignancies cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Ruxolitinib Stanford University | Phase 2 | B |
Treg Cells Stanford University | Phase 2 | B |
Domatinostat 4SC AG | Phase 1 | CC |
Devimistat Wake Forest University Health Sciences | Phase 1 | CC |
Plerixafor Stanford University | Phase 1 | CC |
wj01024 Suzhou Junjing BioSciences Co., Ltd. | Phase 1 | CC |
Enzomenib Sumitomo Pharma America, Inc. | Phase 1 | CC |
Same molecule, other indications
cd4+cd25+ regulatory t cells is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →